Sol-Gel's Collaboration Partner First-To-File ANDA Drug Product Generic To Zoryve Cream Indicated For Plaque Psoriasis In Patients Six Years Of Age And Older
Portfolio Pulse from Benzinga Newsdesk
Sol-Gel Technologies' collaboration partner, Arcutis Biotherapeutics, has initiated a patent infringement action against Padagis concerning a generic version of Zoryve Cream for plaque psoriasis. The lawsuit was filed in the U.S. District Court for the District of New Jersey on March 26, 2024.
April 01, 2024 | 11:19 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sol-Gel Technologies may experience indirect impact due to its partner Arcutis Biotherapeutics' legal action against Padagis over a generic version of Zoryve Cream.
While Sol-Gel Technologies is not directly involved in the lawsuit, its association with Arcutis Biotherapeutics and the outcome of the legal action could indirectly affect its financial or market position, especially if the lawsuit impacts the commercialization or profitability of Zoryve Cream.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70